Will Garvin, shareholder in the firm's Life Sciences industry group, edited "How Will FDA Bring order to the Wild West of Cannabis Regulations?," published in the Food and Drug Law Institute. The article discusses a recent FDA public hearing that enabled relevant stakeholders to discuss their experiences and challenges in an industry that struggles with lack of guidance or regulation from the federal agencies that have jurisdiction of its products.